Log in

NASDAQ:SVRASavara Stock Price, Forecast & News

$2.04
+0.01 (+0.49 %)
(As of 04/8/2020 01:39 AM ET)
Add
Compare
Today's Range
$1.94
Now: $2.04
$2.12
50-Day Range
$1.80
MA: $2.32
$2.72
52-Week Range
$0.69
Now: $2.04
$11.96
Volume340,345 shs
Average Volume523,002 shs
Market Capitalization$103.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Read More
Savara logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-614-1848

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$5.83 per share
Book Value$2.47 per share

Profitability

Net Income$-78,170,000.00

Miscellaneous

EmployeesN/A
Market Cap$103.71 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.


Savara (NASDAQ:SVRA) Frequently Asked Questions

How has Savara's stock been impacted by COVID-19 (Coronavirus)?

Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SVRA stock has decreased by 13.6% and is now trading at $2.04. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Savara?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Savara.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Savara.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) announced its quarterly earnings data on Thursday, March, 12th. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.31. View Savara's earnings history.

What price target have analysts set for SVRA?

6 brokerages have issued 1-year target prices for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they expect Savara's stock price to reach $8.60 in the next twelve months. This suggests a possible upside of 321.6% from the stock's current price. View analysts' price targets for Savara.

Has Savara been receiving favorable news coverage?

Press coverage about SVRA stock has trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Savara earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutSavara.

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $2.04.

How big of a company is Savara?

Savara has a market capitalization of $103.71 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.  View additional information about Savara.

What is Savara's official website?

The official website for Savara is http://www.savarapharma.com/.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: Insider Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel